Immatics Historical Financial Ratios
IMTXW Stock | USD 0.41 0.01 2.38% |
Immatics Biotechnologies is lately reporting on over 76 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 3.58 or Days Sales Outstanding of 26.28 will help investors to properly organize and evaluate Immatics Biotechnologies financial condition quickly.
Immatics |
About Immatics Financial Ratios Analysis
Immatics BiotechnologiesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Immatics Biotechnologies investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Immatics financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Immatics Biotechnologies history.
Immatics Biotechnologies Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Immatics Biotechnologies stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Immatics Biotechnologies sales, a figure that is much harder to manipulate than other immatics biotechnologies GmbH multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Tangible Asset Value
The total value of a company's physical, tangible assets, excluding intangible assets like patents and trademarks.Return On Tangible Assets
A profitability metric that measures a company's ability to generate earnings from its tangible assets.Most ratios from Immatics Biotechnologies' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Immatics Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in immatics biotechnologies GmbH. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. At this time, Immatics Biotechnologies' Capex To Operating Cash Flow is fairly stable compared to the past year. Days Payables Outstanding is likely to climb to 28.09 in 2024, whereas Days Sales Outstanding is likely to drop 26.28 in 2024.
2021 | 2022 (projected) | Payables Turnover | 29.1 | 26.53 | Days Of Inventory On Hand | 4.0E-6 | 3.0E-6 |
Immatics Biotechnologies fundamentals Correlations
Click cells to compare fundamentals
Immatics Biotechnologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immatics Biotechnologies fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 31.62 | 13.56 | 21.39 | 3.16 | 14.21 | 13.5 | |
Ptb Ratio | (13.94) | 4.06 | 30.9 | 2.57 | 3.41 | 3.58 | |
Days Sales Outstanding | 53.87 | 34.14 | 7.16 | 4.52 | 27.67 | 26.28 | |
Book Value Per Share | (0.65) | 2.17 | 0.38 | 3.17 | 2.79 | 2.93 | |
Free Cash Flow Yield | 0.12 | (0.22) | (0.12) | 0.17 | (0.0166) | (0.0158) | |
Operating Cash Flow Per Share | 1.13 | (1.78) | (1.3) | 1.49 | 0.23 | 0.24 | |
Stock Based Compensation To Revenue | 0.0462 | 0.73 | 0.76 | 0.13 | 0.38 | 0.33 | |
Capex To Depreciation | 0.58 | 1.7 | 1.08 | 0.89 | 4.28 | 4.49 | |
Pb Ratio | (13.94) | 4.06 | 30.9 | 2.57 | 3.41 | 3.58 | |
Ev To Sales | 26.2 | 7.12 | 17.85 | 2.39 | 10.45 | 9.93 | |
Free Cash Flow Per Share | 1.09 | (1.94) | (1.39) | 1.4 | (0.16) | (0.17) | |
Roic | 0.77 | (0.8) | (3.65) | 0.13 | (0.45) | (0.43) | |
Payables Turnover | 8.24 | 26.27 | 29.1 | 26.53 | 15.48 | 15.16 | |
Sales General And Administrative To Revenue | 0.64 | 1.09 | 0.97 | 0.21 | 0.71 | 1.03 | |
Research And Ddevelopement To Revenue | 2.17 | 2.15 | 2.52 | 0.62 | 2.2 | 3.42 | |
Capex To Revenue | 0.12 | 0.24 | 0.16 | 0.036 | 0.57 | 0.6 | |
Cash Per Share | 1.9 | 4.83 | 2.31 | 5.39 | 5.29 | 2.74 | |
Pocfratio | 8.22 | (4.95) | (9.09) | 5.46 | 42.1 | 44.2 | |
Interest Coverage | (194.19) | (241.23) | (50.0) | 3.62 | (122.41) | (128.53) | |
Capex To Operating Cash Flow | 0.0315 | (0.0879) | (0.0692) | 0.0621 | 1.7 | 1.78 | |
Pfcf Ratio | 8.49 | (4.55) | (8.5) | 5.82 | (60.28) | (57.27) | |
Days Payables Outstanding | 44.3 | 13.9 | 12.54 | 13.76 | 23.58 | 28.09 | |
Income Quality | (2.18) | 0.37 | 0.88 | 2.67 | (0.19) | (0.18) | |
Roe | 0.76 | (2.2) | (3.95) | 0.18 | (0.43) | (0.45) | |
Ev To Operating Cash Flow | 6.81 | (2.6) | (7.59) | 4.12 | 30.96 | 32.5 | |
Pe Ratio | (18.38) | (1.85) | (7.82) | 14.58 | (7.91) | (8.31) | |
Return On Tangible Assets | (0.24) | (0.9) | (0.55) | 0.0924 | (0.19) | (0.2) | |
Ev To Free Cash Flow | 7.03 | (2.39) | (7.1) | 4.4 | (44.33) | (42.11) | |
Intangibles To Total Assets | 0.007507 | 0.003585 | 0.00753 | 0.004002 | 0.002986 | 0.002837 | |
Net Debt To E B I T D A | 3.43 | 3.12 | 1.47 | (2.68) | 2.28 | 1.63 | |
Current Ratio | 1.79 | 3.94 | 1.6 | 3.54 | 2.87 | 2.1 | |
Tangible Book Value Per Share | (0.67) | 2.15 | 0.36 | 3.15 | 2.78 | 2.91 | |
Receivables Turnover | 6.78 | 10.69 | 50.97 | 80.69 | 13.19 | 21.92 | |
Graham Number | 2.75 | 15.28 | 3.61 | 6.31 | 8.7 | 5.07 | |
Shareholders Equity Per Share | (0.67) | 2.17 | 0.38 | 3.17 | 2.79 | 2.93 | |
Capex Per Share | 0.0355 | 0.16 | 0.0899 | 0.0925 | 0.38 | 0.4 | |
Graham Net Net | (0.84) | 1.78 | (0.0788) | 2.52 | 1.79 | 1.88 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.